Bausch + Lomb Secures $2.8 Billion Refinancing, Extends Debt Maturity

Event summary

  • Bausch + Lomb completed a refinancing of $2.802 billion in outstanding Term B loans.
  • The refinancing involves a fourth amendment to the existing credit agreement, creating 'Replacement Term Loans'.
  • The new loans extend the maturity date from September 29, 2028, to January 15, 2031.
  • The applicable margin on the Replacement Term Loans has been reduced by 0.25% to 0.50% compared to previous loans.
  • The amortization rate for the Replacement Term Loans is 1.00% per annum, with the first installment due June 30, 2026.

The big picture

This refinancing provides Bausch + Lomb with a more manageable debt profile and increased runway, but it doesn't fundamentally alter the company's high-leverage position. The deal reflects ongoing pressure on companies in the healthcare sector to optimize capital structures amidst rising interest rates and economic uncertainty. The extension of the maturity date allows management to focus on operational improvements and potential strategic acquisitions, but also increases scrutiny on their ability to service the debt.

What we're watching

Cost of Capital
The margin reduction suggests Bausch + Lomb was able to negotiate favorable terms, but the sustainability of these rates will depend on broader interest rate trends and the company's performance.
Debt Burden
While the refinancing extends maturity, the substantial debt load remains a key factor in Bausch + Lomb’s financial flexibility and ability to pursue strategic initiatives.
Financial Performance
The company’s ability to meet the new amortization schedule will be directly tied to its operational performance and cash flow generation in the coming years.

Related topics

Interest Rates